Diagnostics: Page 37


  • Abbott antigen test gets FDA nod as first at-home, virtually guided COVID-19 diagnostic

    BinaxNOW requires a prescription and a telehealth service to take users through collection. However, public health experts question why prescriptions are being required at all for such tests.

    By Dec. 17, 2020
  • Image attribution tooltip
    Getty Images
    Image attribution tooltip

    FDA grants EUA for first fully at-home COVID-19 test without a prescription

    The rapid antigen test from Australian company Ellume will be available over the counter for people with or without symptoms and delivers results in about 20 minutes.

    By Dec. 15, 2020
  • the FDA Headquarters Explore the Trendline
    Image attribution tooltip
    Sara Silbiger via Getty Images
    Image attribution tooltip
    Trendline

    Top 5 stories from MedTech Dive

    From haphazard layoffs at the Food and Drug Administration to the industry’s current IPO environment and tracking FDA-authorized AI devices, here is a collection of top stories from MedTech Dive.

    By MedTech Dive staff
  • Deep Dive

    MDR-IVDR bottleneck persists as EU launches 1st Eudamed module

    "Very few notified bodies at this moment in time are taking new products on under the old directive, because a medical device doesn't just get certified overnight," an official at Ireland's National Standards Authority said.

    By Nicholas Wallace • Dec. 14, 2020
  • Image attribution tooltip
    Courtesy of Roche
    Image attribution tooltip

    Roche and Siemens COVID-19 antibody tests shine in FDA accuracy roundup

    Abbott's tests seemed to perform slightly worse than the best serology assays but comparably to kits from some other leading diagnostic players such as Beckman Coulter. 

    By Dec. 14, 2020
  • UK shares post-Brexit device guidance as uncertainty around EU split looms

    MHRA this week outlined which medtech manufacturers will need to register and when. The timeline is determined by the previously disclosed grace period which ends Jan. 1, 2021.

    By Dec. 11, 2020
  • Image attribution tooltip
    Jacob Bell / BioPharma Dive
    Image attribution tooltip

    LabCorp gets EUA for first at-home collection COVID-19 test with no prescription

    The lab giant is selling the kit through its consumer-focused Pixel website and may expand into retail channels. The agency is hoping the over-the-counter diagnostic will spur more testing.

    By Dec. 10, 2020
  • Image attribution tooltip
    Courtesy of Roche
    Image attribution tooltip

    Roche, Thermo Fisher ally with COVID-19 vaccine developers on antibody testing

    The companies are working with Moderna and the University of Oxford to quantitatively measure the antibody levels of recipients of the shots.

    By Dec. 10, 2020
  • Qiagen
    Image attribution tooltip
    Courtesy of Qiagen
    Image attribution tooltip

    Qiagen ups outlook, predicts double-digit non-COVID product growth amid analyst skepticism

    Wall Street is not yet persuaded the company's post-pandemic future is bright. William Blair analysts said they want to "see some signs of execution on growth in a post-COVID-19 world." 

    By Dec. 9, 2020
  • Abbott Laboratories
    Image attribution tooltip
    Courtesy of Abbott
    Image attribution tooltip
    Dive Awards

    Company of the Year: Abbott

    Demand for the diversified medtech's array of coronavirus tests puts it on solid financial ground going into 2021, amid a challenging year for the medical device industry.

    By Maria Rachal • Dec. 9, 2020
  • Image attribution tooltip
    Permission granted by Quidel Corporation
    Image attribution tooltip
    Dive Awards

    Executive of the Year: Doug Bryant, Quidel

    The veteran of Abbott has been at the helm for nearly 12 years, setting the company up for opportunities when the COVID-19 pandemic hit in early 2020 to leverage its point-of-care antigen testing.

    By Dec. 9, 2020
  • A picture of the exterior of the US Department of Health and Human Services. In front of the building is a black sign designating the building's name.
    Image attribution tooltip
    Alex Wong via Getty Images
    Image attribution tooltip
    Dive Awards

    Regulatory Disruption of the Year: HHS lab developed test policy

    The surprise move to no longer require FDA premarket review for laboratory developed tests spurred backlash across a spectrum of public health experts and industry.

    By Dec. 9, 2020
  • The MedTech Dive Awards for 2020
    Image attribution tooltip
    Brian Tucker/MedTech Dive
    Image attribution tooltip
    Dive Awards

    The MedTech Dive Awards for 2020

    From the relentless demand for COVID-19 tests to the pressure on medtechs' traditional business lines, the industry has faced unprecedented market forces this year.

    By MedTech Dive Team • Dec. 9, 2020
  • Quest Diagnostics COVID-19 test home collection kit
    Image attribution tooltip
    Retrieved from Quest Diagnostics, PRNewswire on May 29, 2020
    Image attribution tooltip

    Quest gets first FDA nod for at-home collection coronavirus-flu combo test

    The lab giant is using Roche’s diagnostic and instrument, which received an emergency use authorization in September, with its own process for testing samples collected by consumers.

    By Dec. 7, 2020
  • Olympus to pay $300M to buy Veran for lung navigation system

    The deal is for $300 million up front, with another $40 million tied to an undisclosed milestone.

    By Dec. 7, 2020
  • Image attribution tooltip
    Jacob Bell
    Image attribution tooltip

    Siemens COVID-19 test gets high marks on FDA sensitivity list, beating Abbott, BD and Roche

    A PerkinElmer test still holds the top position among coronavirus diagnostics least likely to return false negatives.

    By Dec. 4, 2020
  • Image attribution tooltip
    Danielle Ternes
    Image attribution tooltip

    CDRH headed for 'reset' in 2021 after COVID-19 derailed priorities, Shuren says

    After a "massive increase" in work due to the pandemic, the device center anticipates continuing to manage coronavirus projects while also focusing on MDUFA V and new programs.

    By Dec. 3, 2020
  • EU underscores remote notified body audit policy amid pandemic

    MedTech Europe has pressed the Commission to expand such reviews to the incoming MDR and IVDR regs, but a new Q&A notes the scope is limited to the directives and devices considered "clinically necessary" during the crisis.

    By Dec. 3, 2020
  • United States $100 bills
    Image attribution tooltip
    "Money" by Ervins Strauhmanis is licensed under CC BY 2.0
    Image attribution tooltip

    Everlywell raises $175M to expand at-home health testing, virtual care services

    The startup was first to win FDA emergency approval for a COVID-19 test self-collection kit. Sales of most tests are growing more than 100% year over year, driven by deals with Target, Walgreens and CVS, though competition is rising.

    By Dec. 3, 2020
  • Fitbit data suggests potential for early COVID-19 detection using wearables

    While the algorithm would generate far more false than true positives even when prevalence is high, researchers argue it could encourage more testing and precautions. The results have yet to be validated in a prospective study.

    By Dec. 1, 2020
  • Grail inks commercial pact with UK government for multi-cancer blood test

    As competition mounts among liquid biopsy developers, the agreement gives Illumina target Grail the chance to validate its early detection tool in the real world and potentially secure access to the broader U.K. market.

    By Nov. 30, 2020
  • IVDR notified body count inches up to 5 with TÜV Rheinland designation

    The medtech notified bodies trade group urged swift action on potentially delaying the start date for the In Vitro Diagnostic Regulation if designations don't more than double by year's end.

    By Updated Nov. 30, 2020
  • Hospitals adopt new round of elective surgery restrictions, brace for Thanksgiving COVID-19 surge

    The American College of Surgeons is among those placing new emphasis on factoring healthcare worker wellbeing into capacity decisions.

    By Maria Rachal • Nov. 25, 2020
  • Image attribution tooltip
    Jacob Bell / BioPharma Dive
    Image attribution tooltip

    Breast cancer tech among FDA's latest breakthrough nods

    Over the past month, designations for speedier review have also ranged from a migraine treatment to tissue regeneration tech for spinal cord injuries.

    By Nov. 24, 2020
  • MedTech Europe backs proposed EU Health Union but flags potential hangups

    The trade group fears moving responsibility for administering the IVDR and MDR expert panels to the European Medicines Agency could slow deployment.

    By Nov. 20, 2020
  • Notified bodies report early success with remote audits but challenges remain

    While there have been benefits to going remote during the pandemic, 57% of those polled by a European trade group say they take longer than on-site assessments and most encounter problems due to poor network connections.

    By Nov. 20, 2020